Patent intelligence · SI
SI 2158199
PIPERIDINE COMPOUNDS AND USES THEREOF
PIPERIDINE COMPOUNDS AND USES THEREOF
Patent details — SI 2158199
- Jurisdiction
- SI
- Status
- granted
- Grant date
- Feb 28, 2011
- Expiration
- Feb 23, 2031
- Applicant
- ASTRAZENECA AB [SE]
- CPC classes
- A61P/3104, A61P/3112, A61P/4300
Quick answer
SI 2158199 (PIPERIDINE COMPOUNDS AND USES THEREOF) is held by ASTRAZENECA AB [SE]. Status: granted. Granted Feb 28, 2011. Expires Feb 23, 2031 (5 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ASTRAZENECA AB [SE]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61P/3104, A61P/3112, A61P/4300
More from ASTRAZENECA AB [SE]
Related pharmaceutical patents in our USPTO index.
-
IL 240179
Use of a monoclonal, chimeric, human antibody that binds il-5r in the manufacture of a medicament for reducing the numbers of blood basophils in a human subject
granted -
ZA 201308176
THERAPEUTIC TREATMENT
granted -
US 2010280048
Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase
granted -
DO P2009000148
DERIVADOS DE ESTER Y AMIDA DE INDAZOLILO PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR UN RECEPTOR DE GLUCOCORTICOIDES
granted -
EP 2086964
BENZOYLAMINOHETEROCYCLYLVERBINDUNGEN, DIE SICH FÜR DIE BEHANDLUNG EINER DURCH GLK VERMITTELTEN KRANKHEIT EIGNEN
granted -
EP 2079730
MGLUR5-MODULATOREN
granted -
EP 2064340
VERFAHREN ZUR BEWERTUNG VON PATIENTEN BEI DER BEHANDLUNG MIT AUF RET-REZEPTOR-TYROSINKINASE ABZIELENDEN ARZNEISTOFFEN
granted
Frequently asked questions
What is US patent 2158199?
SI 2158199 (PIPERIDINE COMPOUNDS AND USES THEREOF) is held by ASTRAZENECA AB [SE]. Status: granted. Granted Feb 28, 2011. Expires Feb 23, 2031 (5 years remaining) — relevant for patent-cliff and LOE planning.
Who owns SI 2158199?
ASTRAZENECA AB [SE] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does SI 2158199 expire?
Our index shows an expiration date of Feb 23, 2031 (5 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.